Altogether, alternative immunotherapeutic approaches have been explored to how to enhance immunotherapy, increase the effector response, and reduce the inflammatory component, such as TGF‐β and COX‐2 which are both affected on tumor cells and immune cells in CRC via blockade of related immunosuppressive signaling pathways. The gene discussed is TGFB1; the disease is neoplasm.